Amgen is expanding its biotech innovation footprint in San Francisco with two floors of advanced R&D lab space designed to accelerate small molecule drug discovery. By bringing together medicinal chemists, computational and structural biologists, protein scientists, and bioassay experts, we’re fostering deeper collaboration to drive faster innovation. This investment reinforces our leadership in research and development and deepens our commitment to science that serves patients.
About us
Amgen harnesses the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller and longer. We helped establish the biotechnology industry, and we remain on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today. Our investment in research and development has yielded a robust pipeline that builds on our existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. Amgen is one of 30 companies comprising the Dow Jones Industrial Average®, and part of the Nasdaq-100 Index®. In 2024, Amgen was named one of the “World’s Most Innovative Companies” by Fast Company and one of “America’s Best Large Employers” by Forbes. For more information, visit Amgen.com and follow us on X, LinkedIn, Instagram, TikTok, YouTube and Threads. 🔗 Community Guidelines: https://wwwext.amgen.com/community-guidelines 🔗Global Privacy Statement Directory: www.amgen.com/dp Special Advisory: Please be cautious of scam recruitment offers claiming to be from Amgen. Such scams may come from various sources, including fake websites and/or unsolicited emails and seek to obtain personal data or payment from victims by offering jobs that do not exist. Please be advised that Amgen would never ask for payment to progress a job application. When in doubt, please check to see if the position in question is posted on this website before applying. Additionally, please report any suspicious recruiting activity to https://complaint.ic3.gov/ and thank you for your assistance.
- Website
-
http://www.amgen.com
External link for Amgen
- Industry
- Biotechnology Research
- Company size
- 10,001+ employees
- Headquarters
- Thousand Oaks, CA
- Type
- Public Company
- Founded
- 1980
- Specialties
- Biologics, Human therapeutics, and Development of novel products
Locations
Employees at Amgen
Updates
-
🔬 A new option for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) has been approved in the U.S. This milestone advances care for an often-overlooked condition and highlights the scientific shift toward recognizing #CRSwNP as an epithelial-driven disease, not just as a localized sinus condition. With this approval in CRSwNP, we are entering a pivotal new chapter in inflammatory research. Amgen remains committed to working with experts to raise awareness and support for people living with this condition. 🔗 Read more: https://lnkd.in/dArCrXjc
-
This week was more than events — it was about patients. 🫶At each Amgen site, #AmgenMissionWeek2025 showed how our mission comes to life, one inspiring moment at a time.
-
When you join our Ohio facility team, you’ll find many employees like Chevon who are bringing their perspective and experience to the manufacturing world. Her story is just one example of our commitment to build a supportive culture that celebrates each team member. Learn more about our Ohio career opportunities: https://bit.ly/46tCS5x
-
-
#amgenpartner Patients are the heart of #AmgenMissionWeek2025 🫶 Patient influencer William Yank takes you behind the scenes—from lab demos to powerful patient stories—capturing moments that remind us who we’re here for 💙✨ Disclaimer: Amgen has engaged William to share his patient experience and participate in on-campus activities in order to provide Amgen further understanding and insight into patient experiences.
-
#amgenpartner Patients had the mic 🎤 and William Yank had the questions. The result? Honest stories, powerful lessons, and moments you’ll want to hear again. Catch it all from #AmgenMissionWeek2025 ✨ Disclaimer: Amgen has engaged William to share his patient experience and participate in on-campus activities in order to provide Amgen further understanding and insight into patient experiences.
-
#AmgenMissionWeek2025 is here! This year we’re celebrating the powerful moments that transform, and the patients who inspire everything we do. Follow along to see what’s unfolding this week.
-
President Trump has challenged the biopharmaceutical industry to strengthen its commitment to make medicines more affordable for U.S. patients. In response, we are proud to announce AmgenNow™, a new direct-to-patient program starting with Repatha® and cardiovascular disease. Through Amgen’s direct-to-patient option, we are making our innovative cardiovascular medicine available at nearly 60% lower than the current U.S. list price. Learn more about the AmgenNow™ program here: https://amgen.ly/4gTKjXc Prescribing information: https://amgen.ly/4gWKtNz
-
Amgen announces topline results from its Phase 3 trial evaluating cardiovascular outcomes in high-risk patients without prior heart attack or stroke. Learn more about the latest data to be presented at the American Heart Association Scientific Sessions #AHA25. 🔗 https://amgen.ly/4o1O6Em